BioCentury on BioBusiness,
2Q13 Stocks: Biotech needs funding window to stay open
Related tables, figures and sidebars
2Q Financial Markets Preview: Looking for 'growthier'
Monday, April 1, 2013
Buysiders remain bullish on
biotech but enter 2Q13 looking for signs that the market's four-year bull run
may be topping out. They suggest companies - which have been spending cash as
fast as they have been raising it - should take advantage of the sellers'
market while it lasts.
Biotechs have been raising
money hand over fist for several quarters in a row, including more than $780
million that was raised on Jan. 16 alone through follow-ons by cancer company Onyx
Pharmaceuticals Inc. and RNAi play Alnylam Pharmaceuticals Inc.; and
a share and note deal by pulmonary and fibrotic disease company InterMune
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2014 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]